Trinity Resources

Webinars

China NRDL 2025: Locked Out or Leveled Up?

July 8, 2026 | 2:00 – 2:45 PM ET

Additional sessions for EU and APAC

China’s 2025 NRDL update continues to demonstrate constrained willingness to pay while still rewarding truly differentiated therapies. Meanwhile, the emergence of a Commercial Insurance Innovative Drug List (CIIDL, formerly Category C) is creating an alternative access route for highly innovative therapies to preserve price and achieve targeted access.
Register for the Webinar
Filter by Type:
Webinars

China NRDL 2025: Locked Out or Leveled Up?

Register for the Webinar
Briefs

The Pharma Digital/IT Landscape: CMIT Decisions on AI, Data, and Value

Read the Brief
Briefs

Speaker Programs at Scale: How Decisions Hold Up Over Time

Read the Brief
Analyst Reports

Turn Complex Health Data Into AI-Ready Advantage

Read more
Briefs

ForecastEDGE™ and Agentic Forecasting: Turning Forecasts into a Real-Time Decision Engine

Read the Brief
Webinars

Scaling AI Across the Field Force: Governance, Pitfalls, and Proof for Commercial Teams

Watch the Webinar
Webinars

Launch & Learn: Tech-Enabled Launch Excellence

Watch the Webinar
White Papers

Third Annual State of Global Market Access

Read the White Paper
Briefs

South Korea’s Evolving Drug Pricing & Reimbursement Landscape

Read the Brief
Video

Trinity – Powering the Future of Life Sciences Commercialization

Watch the Video
Briefs

Navigating the Shift of Cardiac Care to ASCs: The Imperative for Data Driven Commercial Strategy

Read the Brief
Briefs

Annual State of Learning & Development in Life Sciences: Part III

Read the Brief
Back To Top